We derived the lymphoma cell lines OCI-Ly 13.1 and OCILy 13.2 from a patient with non-Hodgkin's lymphoma at the time of presentation and during chemotherapy-resistant relapse. These lines were of T-cell phenotype and contained the identical T-cell receptor @-chain rearrangement, indicating that both lines were members of the same malignant clone. The lines differed in their growth characteristics; Ocl-Ly 13.1 grew slowly and required growth factors for colony formation, whereas OCI-Ly 13.2 grew rapidly and formed colonies without addition of growth factors. TO test whether or not these biologic differences were associated with specific genetic changes, we evaluated the status of the c-myc and p53 genes of both cell lines. The p53 and c-myc genes of OCI-Ly 13.1 were in germline configuration and produced normal-sized transcripts. The p53 protein expressed in OCl-Ly 13.1 was recognized by M ALIGNANT LYMPHOMAS vary in morphology and clinical behavior.' Some patients with intermediate or high-grade disease are potentially curable. Others achieve a transient remission. Relapsing disease is associated with a poor prognosis and attempts at further therapy are often unsuccessful. This change in response to treatment may reflect disease progression. The exact genetic events responsible for such change in behavior of lymphoma cells have not been definitively identified. Clues as to which genes may be involved in progression have come from classic cytogenetic studies and investigations of oncogenes and tumor-suppressor genes by molecular technique^.^'^ One of the genes that is most frequently altered in a variety of tumors is the p53 tumor-suppressor gene located on chromosome 17 band p13. The p53 gene encodes a 53-kD phosphoprotein that is normally present in the nucleus of cells. Mutations of p53 have been identified in a wide variety of tumors including those of the colon, lung, breast, brain, and soft tissues, as well as in hematologic malignancies."" In colon carcinoma, mutations of p53 have been found to occur late in the course of the d i s e a~e .~~'~ Similarly, in chronic myelogenous leukemia (CML) mutations of p53 are rarely seen in chronic phase, whereas cells from patients in accelerated phase or blast crisis display p53 gene alterations."-13 p53 gene mutations in lymphoid tumors are more frequently observed in patients with advanced dis-
the anti-p53 monoclonal antibody, PAb240, indicating a conformation typical of p53 proteins expressed by p53 alleles containing a missense mutation. However, sequencing studies of the entire p53 coding region did not reveal any point mutations. In contrast, the cell line OCI-Ly 13.2 contained structural abnormalities of both the c-myc and p53 genes. In addition, one of the p53 alleles was lost as determined by a cDNA probe for the p53 gene (1 7p 13.1 ) and the YNZ22.1 probe (17p 13.3). These changes resulted in the absence of p53 protein and mRNA in OCI-Ly 13.2 as detected by immunoprecipitation and Northern blot analysis, respectively. They may be a reflection of disease progression and may be associated with the altered behavior of the malignant cell population within the patient and in vitro. ease.l4.I5 These observations suggest that alterations in the p53 gene may be involved in disease progression.
Another gene that has been associated with disease progression is the c-mvc proto-oncogene, which is located on the long arm of chromosome 8 and encodes a nuclear transcription factor.16 In contrast to p53 protein, which is believed to act as a negative regulator of cell growth, c-myc protein has been shown to promote cell
In experimental models, the c-mycgene will cooperate with other oncogenes, such as activated ras" and b~1-2,~' to induce malignant transformation. Translocations of c-myc are frequently identified in certain tumors of rodents and in human malignancies2'; when present, they are associated with advanced disease. In fact, translocations of the c-myc gene have been implicated in the progression from low-grade follicular lymphoma to high-grade lymphoma. 22 We had the opportunity to treat and study a patient with malignant T-cell lymphoma. Initially, the disease responded to chemotherapy. After a brief remission, the disease recurred and was no longer sensitive to treatment. We were able to derive cell lines at both time points.23 Both linesoriginated from the same T-cell clone. The cell line obtained at presentation (OCI-Ly 13.1) differs from the cell line developed at the time of relapse (OCI-Ly 13.2) with respect to its growth behavior in culture. In order to understand the observed differences in kinetics and growth requirement in culture, we investigated the molecular structure of the myc and p53 genes of both cell lines. Our results show that alterations of myc and p53 genes were linked to the evolution of the malignant clone and may be responsible for disease progression.
MATERIALS AND METHODS
Cell lines. Two cell lines, OCI-Ly 13.1 and OCI-Ly 1 3.2,23 were used for this study. Both cell lines were initiated from bone marrow (BM) samples of a patient with large cell lymphoma. OCI-Ly 13.1 was derived at diagnosis, whereas OCI-Ly 13.2 was established 4 months later, at the time of therapy-resistant relapse. The characteristic properties of these cell lines have been published prev i o~s l y .~~ Phenotypically, the cells are of T-cell origin; the growth characteristics of both lines are summarized in UK)." PAb419, 26 is an anti-SV40 large T-antigen MoAb that also cross-reacts with a 35-kD protein present in mammalian cells: it was obtained from E. Harlow (Massachusetts General Hospital, Boston) and was used in this study as a negative control.
The c-myc probe is a I .4-kb Cla I-EcoR I fragment containing the third coding exon of the c-myc gene on human chromosome 8 (provided by R. Dalla Favera, Columbia University, New York)." The p53 probe is a 1.8-kb cDNA fragment cloned in the pECE vector.2n The plasmid P2E-H2E-H2BX contains a 350-bp p53 genomic fragment encompassing part of the first exon of the p53 gene." The probe for the T-cell receptor (TCR) @-chain is a 770 PSI I fragment of the constant region. It was obtained from T. Mak (Ontario Cancer Institute, Toronto).29 The YNZ22. I probe was provided by Y. Nakamura (Howard Hughes Medical Institute. Salt Lake City, UT)." Immzmoprecipitation. Cells( IO') were labeled with 0.2 mCi "Smethionine in I mL methionine-free a-minimal essential medium (GIBCO, Grand Island, NY) for 1 hour at 37°C. Cells were then washed with phosphate-buffered saline and lysed in 0.3 mL lysis buffer ( I % Nonidet P 4 0 [Sigma Chemical Co. St Louis, MO], I50 mmol/L NaCI, 20 mmol/L Tris (pH 8.0), and 0.5 mmol/L phenylmethylsulfonyl fluoride (Sigma) on ice for I5 minutes. Lysates were centrifuged for I minute and supernatants incubated with 5 pg nonspecific murine MoAb lgG2a (Sigma) overnight at 4"C, followed by immunoprecipitation with 0.5 mL 10% formalin-fixed StaphyloUtes on ice. Precleared lysates containing IO' trichloroacetic acid (Sigma) (TCA)-insoluble cpm were immunoprecipitated with antibodies at 4°C for 2 hours. lmmunocomplexes were collected by incubating samples with 50 pL Staphylococcus aurelcs cells, washed twice in NET/gel buffer (150 mmol/L NaCI, 5 mmol/L EDTA, pH 8.0, 50 mmol/L Tris pH 7.4, 0.05% Nonidet P-40, 0.02% sodium azide, 0.25% gelatin), eluted into 30 pL sample buffer (2% SDS. 0.1 % bromophenol blue. I% glycerol, 25 mmol/L Tris pH 6.8.0. I mmol/L dithiothreitol) by heating at 70°C for IO minutes and loaded on a 14% sodium dodecyl sulfate-polyacrylamide gel. The electrophoresis was performed at 55 mA until the blue front reached the bottom of the gel. Gels were fixed in 7.5% acetic acid and 25% methanol for 30 minutes, dried, and exposed to Kodak XAR-5 film (Eastman-Kodak, Rochester, NY) at room temperature.
Southern blot ana/wis. DNA was extracted from the cell lines OCI-Ly 13.1 and X I -L y 13.2. Control DNA was obtained from normal human skin fibroblasts. The DNA was digested with the appropriate restriction enzymes, fractionated by electrophoresis on 0.8% agarose gels. transferred to Gene-Screen Plus (Dupont CO, Wilmington, DE), hybridized with 3ZP-labeled probes, washed. and exposed to Kodak XAR film with an intensifying screen at -70°C as previously described." Northern blot anal.vsis. RNA was isolated from the cell line OCI-LY 13.1 and OCI-LY 13.2, separated on an agarose-formaldehyde gel. transferred to Gene-Screen Plus, hybridized with "P-labeled probes, washed. and exposed to Kodak XAR film as previously described." The equality of loading was judged by ethidium-bromide staining.
cDNA S-vnthesis and amplifrcation of p53 cDNA by polymerase chain reaction (PCR). First-strand cDNA was prepared from the cell line OCI-Ly 13. I as previously described and used as template for amplification by the PCR.32 The reaction was catalyzed by Taq DNA polymerase using a Perkin-Elmer (Cetus, Nonvalk, C T ) thermocycler for 30 cycles of denaturation (94"C, I min), annealing (65"C, I min), and elongation (72"C, 2 min), followed by a final extension at 72°C for 7 minutes. One pair of primers was used to amplify the p53 cDNA spanning exons 1 through 1 I . 32 The sense primer, 5Sx I , starting at the 3' end of the untranslated exon 1 had the sequence S-GACACTTTGCCTTCGGGCTGGGAG-3'. The antisense primer, JSx3, representing the untranslated region ofexon I I , had the sequence 5'-GAGGGAGAGATGGGGGTGGGAAsymmetric PCR and direct sequencing. Asymmetric PCR reactions were used to generate single-stranded DNA for sequencing. The PCR products derived from the cDNA of OCI-Ly 13. I were copied asymmetrically with either 5Sx I or JSx3 ~rirners.'~ To sequence genomic DNA from OCI-Ly 13. I and OCI-Ly 13.2. DNA was copied asymmetrically with the primer 5Sx4 (sense, exon 4,
OCI-LV20 OCI-Lv13.1 OCI-Lv13. 5'-CCCTTGCCGTCCCAAGCAATGGA-3'). PCR was performed for 30 cycles using the Same temperature changes as described earlier. The reaction mixture was treated with phenol/CHCI, and passed through a spin column ofsephadex G-50 (Pharrnacia, U p p sala, Sweden). The sample was precipitated with ethanol and redissolved in distilled water for direct sequencing.
Sequencing was performed by the dideoxynucleotide-chain termination method using specific p53 primers and DNA polymerase (Sequenase 2.0. US Biochemicals. Cleveland. OH) in the presence of 10% formamide. The sequencing reactions were fractionated on 6%) polyacrylamide gels in TRE and 8 mmol/L urea. The primers used for sequencing PCR products of p53 cDNA were: 5Sx I , 5Sx4, 5Ax4 (antisense. exon 4. 5"GGTGTAGGAGCTGCTGCT-GGTGC-3'). SSxS(sense. exon 5. 5"ACTCCCCTGCCCTCA-CHANG ET AL ACAAG-3'). 3Ax9(antisense. exon 9, 5"GGGTGAAATATTCTCCATCCATCCpAGTGG-3'). and JSx3.'* The 5Sx4 primer was used to sequence PCR products derived from p53-genomic DNA.
RESULTS
TCR rm"unKomen/. DNA prepared from OCI-Ly 13. I and OCI-Ly 13.2 was examined by Southern blot hybridization using a probe for the TCR-P gene. Identical rearrangement patterns of the TCR-8 gene were observed for both cell lines usingeither Hind111 or BamHl restriction enzymes (data not shown). These results indicate that the two lines are members of the same malignant clone. To identify possible genetic changes responsible for the phenotypic differences between the cell lines, we examined the structure and expression of the c-myc and p53 genes, two genes that are associated with disease progrcssion in malignant lymProtein ana/mis. To determine the status of the p53 gene expressed in both cell lines. p53 protein was immunoprecipitated using two different antibodies. PAbl80 1 recognizes all forms of human p53 protein, whereas PAb240 recognizes preferentially mutant p53 protein. Immunoprecipitation of p53 protein from "S-methionine labeled OCILy 13.1 and OCI-Ly 13.2 cell extracts showed that p53 was only present in OCI-Ly 13.1 but not in OCI-Ly 13.2 cells. Fig I shows the precipitation of p53 protein by PAbl801 and PAb240 in OCI-Ly 13.1 lysates: no p53 protein was precipitated by either antibody from lysates of OCI-Ly 13.2 cells. The B-cell lymphoma line denoted as OCI-Ly 20 was used as a control. It is known to express a p53 protein that is recognized by PAb 180 I but not by PAb240. The reactivity of p53 protein with PAb240 expressed in OCI-Ly 13.1 suggests the presence of an aberrant conformation that may result from an underlying missense mutation.
Generic anulwis. To determine whether the absence of p53 protein in OCI-Ly 13.2 was caused by transcriptional regulation, RNA was isolated and analyzed by Northern blot hybridization. As shown in Fig 2, a normal sized 2 .8-kb message was present in OCI-Ly 13. I , but not in OCI-Ly 13.2. To ensure the quality of mRNA in both lines, the same filter was washed and reprobed with the c-myc gene probe. Both lines were found to express c-myc mRNA (Fig 2) . The amount of RNA in each lane was equal as judged by ethidium-bromide staining (data not shown).
phomas. 14.15.22 gene based upon the results of Southem blot analysis. This is only a hypothetical map and will need to be confirmed by cloning and sequencing. The cDNA probe for the coding region of p53 is denoted as (a). The genomic DNA probe for exon 1 is shown as (b).
For The lack of p53 RNA in OCI-Ly 13.2 might be related to a structural alteration of the p53 gene. To determine if this was the case, genomic DNA was digested with a variety of restriction enzymes and Southern blots probed with fragments of DNA representing different regions of the p53 gene. DNA of OCI-Ly 13.1 digested with restriction enzymes EcoRI, Bgfll or BamHI and probed with a full-length p53 cDNA probe gave the expected pattern of germline bands (Fig 3 and Table 2 ). However, DNA prepared from OCI-Ly 13.2 showed rearrangements of the p53 gene with each of the restriction enzymes. The expected size of fragments obtained with EcoRI, BarnHI and Bgfll are shown in Fig 4 and in Table 2 . Digestion of DNA with EcoRl normally produces two 15-kb fragments, however in OCI-Ly 13.2 there were bands of I5 and 19 kb. Digestion of DNA with BgflI normally produces fragments of 12 and 3.7 kb. In DNA from OCI-Ly 13.2 the 3.7 kb band was present. The 12-kb band was missing and a new band of I6 kb was observed. Digestion of normal DNA with BarnHI results in germline bands of I3 and 7.8 k b the 13-kb fragment is often not seen, probably because of the small amount of exon present in the probe. DNA from OCI-Ly 13.2 digested with BarnHI contained a germline band of 7.8-kb and a new band of 4 kb. Digestion of OCI-Ly 13. I and X I -L y 13.2 DNA with Hind111 and probed with the p53 cDNA showed bands of 7 and 2.5 kb similar to the germline pattern. To assess the status of exon I , DNA was digested with EcoRI and BamHI and probed with a genomic fragment containing exon l : germline sized bands of 3.5 and 13 kb, respectively, were observed (Fig 5) .
The results of the Southern blot analysis are summarized in Table 2 . Digestion of DNA with Hindlll gave a germline pattern indicating that the Hindlll site just 5' of exon 2 and the two Hind111 sites 3' of exon 2 were intact. However, digestion of DNA with EcoRI, BgflI and BarnHl indicated that the gene had undergone a rearrangement. Based on the finding that the 5"EcoRI and Bghl fragments were 4 kb larger than expected, whereas the 3' fragments were of normal size, it is likely that a DNA rearrangement had occurred between the &Ill site in intron I and the Hind111 site just 5' of exon 2. The fact that both the new EcoRI and BgnI fragments were 4 kb larger than expected and that the first exon was intact suggests that the rearrangement is caused by an insertion rather than a translocation or deletion (Fig 4B) . Verification of this will require cloning of the p53 gene from
The above studies indicate that the p53 gene is altered in OCI-Ly 13.2. In addition, the results suggest that there has been loss of one copy of the p53 gene. In a cell carrying two copies of the p53 gene in which one of the copies had been rearranged, one would expect to see a germline pattern and evidence of rearrangement. In OCI-Ly 13.2 a normal p53 germline pattern was not seen. Allelic loss was confirmed by use of the probe pYNZ22.1 which detects a highly polymorphic region ( I 7p 13.3) that is closely linked to the p53 gene on chromosome I7p. DNA of OCI-Ly 13. I digested with BarnHl resulted in 2 bands. In contrast, only the smaller band was present in BarnHI-digested OCI-Ly 13.2 DNA (Fig 6) .
Soulhern blot ana1.vsis of myc. When DNA from OCILy 13.1 was digested with EcoRl and probed with c-myc, a 13-kb germline band was seen. In contrast, OCI-Ly 13.2 DNA contained two fragments of I3 and I5 kb that hybridized with the c -m y probe (Fig 7) indicating rearrangement of one of the c-mvc alleles. Sequencing analJ).qis. The presence of PAb240 + p53 protein in OCI-Ly 13.1 cells suggested a putative mutation in the p53 gene. Therefore we sequenced the entire coding region of p53 cDNA from OCI-Ly 13.1. One nucleotide change (CCC-CGC) was identified at codon 72 that converts proline to arginine (Fig 8A) . This has been shown to be a naturally occurring polymorphism in the human p53 coding sequence.33 Although this change alters the electrophoretic mobility of p53 protein, it is not believed to alter the biologic activity or the immunologic reactivity of wild-type p53 protein. No other differences were found in the p53 cDNA from OCI-Ly 13.1. As expected, the codon for arginine at position 72 was also found in the genomic DNA of by Southern blot analysis using
C-MYC
OCI-Ly 13.2 ( Fig 8C) . No primary tumor sample DNA was available to determine whether the changes present in OCILy 13.2 were in the presentation or relapse samples. It is possible that the changes in OCI-Ly 13.2 arose during the establishment of the cell line. however, our experience with other cell lines indicates that this is unlikely.
DISCUSSION
The derivation of two cell lines from a lymphoma patient at diagnosis and during relapse provided the unique opportunity to examine genetic events that may be associated with progression of disease as shown by the clinical course of the patient. We focused on investigations of the p53 and c-myc gene because a series of previous studies suggested their involvement in disease progression.9"5~'R~~"~~~ The results of our studies are summarized in Table 3 . Immunoprecipitation studies of OCI-Ly 13. l-derived lysates showed the presence of a PAb24O-reactive p53 protein. This form of reac- In contrast, OCI-Ly 13.2 neither contained detectable p53 protein by immunoprecipitation nor p53 mRNA by Northern blot analysis. The loss of p53 expression in OCI-Ly 13.2 was the result of two independent events. The changes included rearrangement of one p53 allele and loss of the second allele. The loss ofone p53 allele at I7p 13.1 was associated with a loss of a highly polymorphic locus at 17pl3. In addition, we were able to observe changes in c-myc. OCI-Ly 13.1 showed c -m y in germline configuration. In contrast, OCI-Ly 13.2 presented with a rearrangement of one allele of c-myc. Although the significance of this rearrangement on c-myc expression in OCI-Ly 13.2 is unknown, c-myc gene rearrangements have been associated with deregulation of expression."." In a previous study, we noted an association between mutant forms of p53 and cmyc rearra~~gement.~' A similar observation has also been made in Burkitt's-lymphoma cells where the majority of studied cases have both a rearranged c-myc and a mutatedor deleted-p53 gene?', 42 The significance of this association is not clear. In addition to the alterations of myc and p53 other genetic changes may have occurred that differentiate OCI-Ly 13. I from OCI-Ly 13.2. The mechanism resulting in the observed changes is unknown but may be related to an intrinsic genetic instability ofthe cells or as a result ofthe chemotherapy given to the patient at presentation. Both cell lines will be of value to investigate the role of mvc. p53 or other genes that have undergone genetic modifications in the progression of malignant clones.
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